|
|
|
|
|
|
|
24.12.25 - 13:03
|
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration (Business Wire)
|
|
|
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”).
“We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “This marks the third and most significant portfolio transaction for Repare this year.”
Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities.
On...
|
|
|
|
|
|
|
|
|
|
|
20.12.25 - 09:12
|
Trump strikes deal with US drugmakers to cut Medicaid medicine costs (The Guardian)
|
|
|
Officials pledge 'massive savings' as companies agree to offer drugs at prices paid in other wealthy countriesDonald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche's US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on. Continue reading......
|
|
|
|
|
19.12.25 - 21:21
|
Neun weitere Pharma-Unternehmen senken Preise in den USA (Dow Jones)
|
|
|
eun Pharmaunternehmen wollen in den USA die Preise senken. Die Gesellschaften haben sich gegenüber der US-Regierung bereit erklärt, bestimmte US-Preise für ihre Medikamente zu senken. Die Unternehmen stimmten zu, die US-Preise für Medikamente auf ein Niveau zu senken, das mit den Preisen in anderen wohlhabenden Ländern vergleichbar ist, die im Allgemeinen viel niedriger sind. Diese "Meistbegünstigten"-Preise gelten für das US-Medicaid-Programm für Patienten mit geringerem Einkommen, für Direkt-an-Patienten-Dienste einschließlich des geplanten TrumpRx und für neu eingeführte Medikamente in der Zukunft..
|
|
|
18.12.25 - 14:33
|
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day.
Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Partners team. She previously led the Litigation and Government Investigations and the Corporate Governance and Strategic Transactions teams. Ms. Wettan has been instrumental in supporting the launch of groundbreaking medicines, including the recent launch of lenacapavir, a breakthrough twice-yearly HIV prevention medicine. She also currently serves as the Chair of the Board of the Gilead Foundation.
“Keeley is an accomplished executive who brings deep legal expertise, and who leads with integrity, passio...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
